Skip to main content
. 2013 Aug 27;56(8):343–350. doi: 10.3345/kjp.2013.56.8.343

Table 3.

Treatment response to imatinib given to patients diagnosed in chronic phase

graphic file with name kjped-56-343-i003.jpg

CHR, complete hematologic response; CCyR, complete cytogenetic response; MMR, major molecular response; FU, follow-up; CMR, complete molecular response; NA, not achieved; NE, not evaluable; FU, follow-up.

*Transferred to another hospital using imatinib mesylate without disease progression. Alive with next generation tyrosine kinase inhibitor after disease progression.